key
driver
biopharmaceut
invest
decis
probabl
success
drug
develop
program
estim
probabl
success
po
clinic
trial
vaccin
antiinfect
therapeut
use
uniqu
triplet
clinic
trial
drug
diseas
januari
januari
yield
vaccin
program
nonvaccin
program
target
infecti
diseas
overal
estim
po
industrysponsor
vaccin
program
industrysponsor
antiinfect
therapeut
among
industrysponsor
vaccin
program
diseas
categori
seen
least
one
approv
success
monkeypox
rotaviru
japanes
enceph
three
infecti
diseas
highest
po
industrysponsor
nonvaccin
therapeut
smallpox
cmv
onychomycosi
nonindustrysponsor
vaccin
nonvaccin
develop
program
lower
overal
poss
respect
virus
involv
recent
outbreaksm
sar
ebola
zikahav
combin
total
nonvaccin
develop
program
initi
past
two
decad
approv
therapi
date
note
data
obtain
outbreak
contain
inform
program
target
diseas
estim
offer
guidanc
biopharma
investor
well
policymak
seek
identifi
area
like
undeserv
privatesector
engag
need
publicsector
support
paper
provid
estim
histor
probabl
success
po
clinic
trial
vaccin
therapeut
drug
infecti
diseas
inform
discuss
plan
financ
fight
one
human
oldest
foe
particular
import
light
recent
havoc
wreak
sever
acut
respiratori
syndrom
coronaviru
viru
caus
coronaviru
diseas
probabl
success
therapeut
drug
variou
diseas
group
like
oncolog
welldocu
abrantesmetz
et
al
dimasi
et
al
hay
et
al
mit
laboratori
financi
engin
smietana
et
al
thoma
et
al
wong
et
al
wong
et
al
rel
littl
publish
treatment
infecti
diseas
vaccin
develop
despit
import
davi
et
al
pronker
et
al
prior
studi
focus
narrow
subset
relev
specif
interest
reli
much
limit
data
set
exampl
young
et
al
employ
data
point
per
estim
valu
bill
melinda
gate
foundat
estim
po
vaccin
neglect
diseas
dimasi
et
al
report
po
estim
perdrug
basi
use
trial
diseas
interest
gate
foundat
contrast
employ
much
larger
broader
dataset
uniqu
clinic
trial
estim
po
vaccin
nonvaccin
therapeut
target
differ
infecti
diseas
use
avail
drugind
pairsa
methodolog
argu
relev
evalu
drug
develop
r
risk
product
hay
et
al
thoma
et
al
wong
et
al
vaccin
commonli
recogn
one
costeffect
public
health
measur
combat
infecti
diseas
ehreth
kieni
girard
oecd
pronker
et
al
et
al
develop
countri
routin
prophylact
vaccin
effect
treatment
option
led
control
complet
elimin
sever
deadli
infecti
diseas
individu
herd
immun
prevent
million
death
untold
suffer
year
prophylaxi
dramat
reduc
burden
healthcar
system
societi
whole
addit
death
hospit
treatment
cost
avoid
measur
led
signific
econom
save
ehreth
et
al
us
depart
health
human
servic
technolog
continu
advanc
one
expect
human
speci
better
abl
cope
diseas
fact
remain
howev
still
effect
treatment
vaccin
mani
infecti
diseas
discoveri
antibiot
reduc
mortal
rate
bacteri
infect
develop
smallpox
vaccin
led
erad
devast
diseas
world
health
organ
infecti
diseas
acquir
immunodefici
syndrom
aid
drug
develop
program
clinic
investig
use
drug
diseas
typic
consist
sequenti
clinic
trial
separ
phase
make
assumpt
program
must
transit
phase
phase
phase
approv
say
drug
develop
program
reach
phase
observ
infer
least
one
trial
phase
probabl
drug
develop
program
transit
phase
phase
j
posij
comput
use
simpl
ratio
njni
ni
number
drug
develop
program
initi
phase
known
outcom
phase
phase
j
j
denot
regulatori
approv
nj
number
drug
develop
program
among
former
made
phase
j
call
estim
probabl
drug
develop
program
transit
phase
phase
phase
po
estim
overal
po
defin
estim
probabl
drug
develop
program
go
phase
regulatori
approv
least
one
countri
estim
probabl
drug
develop
program
transit
phase
approvalestim
directli
use
method
describ
abovei
call
pathbypath
estim
overal
po
report
po
calcul
emphas
treatment
inprogress
drug
develop
program
pathbypath
po
estim
multipl
ie
po
po
po
po
contrast
phasebyphas
estim
multipli
see
wong
siah
lo
http
projectalphamitedufaq
detail
illustr
exampl
simplifi
terminolog
henceforth
omit
qualifi
estim
refer
po
understood
po
valu
report
articl
statist
estim
unobserv
popul
paramet
apr
wong
siah
lo
page
right
reserv
identifi
phase
transit
make
standard
assumpt
phase
phase
trial
consid
phase
phase
respect
report
drug
develop
program
seen
least
one
trial
definit
outcom
extract
clinic
trial
metadata
januari
snapshot
citelin
pharmaproject
trialtrov
databas
provid
informa
pharma
intellig
clinic
trial
metadata
retriev
trialtrov
databas
approv
data
obtain
pharmaproject
databas
requir
identifi
drug
develop
program
databas
contain
inform
us
nonu
sourc
consid
drug
approv
approv
countri
clinic
trial
use
analysi
end
date
januari
start
date
januari
filter
data
includ
trial
tag
citelin
infecti
diseas
vaccin
infecti
diseas
therapeut
area
vaccin
type
diseas
provid
databas
databas
encod
uniqu
triplet
trial
identif
number
drug
diseas
data
point
singl
trial
repeat
multipl
data
point
sinc
two
therapeut
area
may
overlap
data
point
defin
clinic
trial
involv
vaccin
develop
part
vaccin
develop
program
addit
process
data
specif
diseas
eg
rabi
identifi
instead
broad
vaccin
class
eg
vectorborn
diseas
vaccin
clinic
trial
involv
vaccin
develop
program
deem
part
nonvaccin
drug
develop
program
deriv
data
point
total
defin
industrysponsor
develop
program
one
least
one
commerci
compani
involv
stage
clinic
develop
complementin
commerci
compani
involv
stage
vaccin
drug
develop
programshal
refer
nonindustrysponsor
plot
number
develop
program
known
start
month
januari
decemb
figur
industrysponsor
nonindustrysponsor
vaccin
develop
program
respect
industrysponsor
nonindustrysponsor
nonvaccin
drug
develop
program
target
infecti
diseas
respect
seen
figur
number
industrysponsor
clinic
program
attempt
treat
infecti
diseas
often
greater
number
vaccin
develop
program
gap
number
program
initi
develop
type
seem
increas
januari
may
declin
see
section
detail
analysi
see
precipit
fall
number
infecti
diseas
treatment
develop
program
initi
late
like
relat
declin
invest
research
develop
r
novel
antibiot
apr
wong
siah
lo
page
right
reserv
precipit
closur
antibiot
biotechnolog
firm
withdraw
pharmaceut
compani
antibiot
busi
hu
langreth
januari
june
number
nonindustrysponsor
vaccin
develop
program
initi
par
number
nonindustrysponsor
nonvaccin
antiinfect
drug
develop
program
initi
see
figur
howev
number
nonvaccin
drug
develop
program
initi
begin
outpac
number
vaccin
develop
program
januari
experi
rapid
boom
declin
rapidli
octob
januari
vaccin
treatment
infecti
diseas
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
overal
vaccin
develop
program
observ
dataset
sponsor
industri
involv
industri
sponsor
stage
develop
industrysponsor
drug
develop
program
respiratori
infect
activ
research
vaccin
categori
compris
vaccin
develop
program
see
figur
hepat
b
viru
hbv
human
immunodefici
viru
hiv
vaccin
repres
vaccin
develop
program
respect
wherea
intraabdomin
infect
monkey
pox
sever
acut
respiratori
syndrom
sar
vaccin
least
research
field
one
develop
path
observ
per
diseas
similar
pattern
seen
nonindustrysponsor
vaccin
develop
program
exclud
other
categori
top
three
research
vaccin
categori
also
respiratori
infect
hiv
hbv
wherea
middl
east
respiratori
syndrom
mer
sar
least
research
diseas
one
develop
program
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
apr
wong
siah
lo
page
right
reserv
figur
see
overal
po
industrysponsor
vaccin
develop
program
standard
error
se
substanti
higher
averag
overal
po
se
across
industrysponsor
drug
develop
program
see
tabl
despit
fact
latter
comput
estim
use
differ
method
phasebyphas
approach
consid
lead
indic
estim
se
se
se
respect
across
industrysponsor
vaccin
develop
program
see
monkeypox
vaccin
development
success
follow
rotaviru
japanes
enceph
vaccin
see
figur
overal
success
rate
se
se
se
respect
po
monkeypox
base
one
sampl
diseas
diseas
categori
least
one
develop
path
observ
seen
least
one
approv
vaccin
contrast
nonindustrysponsor
vaccin
develop
program
overal
po
se
estim
se
se
se
respect
figur
top
three
indic
highest
overal
success
rate
nonindustrysponsor
drug
develop
program
otiti
media
se
rabi
se
japanes
enceph
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
apr
wong
siah
lo
page
right
reserv
se
latter
estim
deriv
hand
sampl
must
interpret
caution
larg
standard
error
suggest
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
contrast
vaccin
intend
prevent
diseas
number
altern
develop
treatand
case
curepati
afflict
infecti
diseas
accord
dataset
industrysponsor
nonindustrysponsor
nonvaccin
drug
develop
program
respect
initi
area
infecti
diseas
see
figur
top
three
diseas
greatest
number
industrysponsor
drug
develop
program
respiratori
infect
hiv
hepat
c
viru
hcv
togeth
compris
industrysponsor
nonvaccin
develop
program
nonindustri
antiinfectiousdiseas
drug
develop
program
focu
treat
respiratori
infect
hiv
bacteria
skin
infect
respect
address
recent
viru
outbreaksm
sar
ebola
zikaa
total
industrysponsor
nonindustrysponsor
nonvaccin
drug
develop
program
initi
past
twenti
year
approv
therapi
date
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
figur
see
overal
po
across
industrysponsor
drug
develop
program
treat
infecti
diseas
se
se
se
se
respect
base
data
highest
success
rate
industrysponsor
nonvaccin
develop
program
smallpox
se
cmv
infect
se
onychomycosi
se
current
nonvaccin
therapi
approv
rotaviru
sar
rabi
ebola
west
nile
viru
wnv
marburg
yellow
fever
chikungunya
mer
monkeypox
noroviru
except
noroviru
mer
diseas
without
vaccin
predominantli
preval
nonindustri
nation
thu
repres
neglect
diseas
also
interest
latter
eight
diseas
even
low
sinc
phase
trial
develop
antiinfect
therapi
focu
primarili
safeti
understand
pharmacokinet
compound
maximum
toler
dose
level
infer
drug
test
either
high
toxic
lack
necessari
characterist
requir
optim
absorpt
distribut
metabol
excret
odm
perhap
fail
advanc
due
financi
constraint
nonindustrysponsor
nonvaccin
develop
program
overal
po
se
se
se
se
respect
see
figur
top
three
indic
highest
overal
success
rate
nonindustrysponsor
nonvaccin
develop
program
cmv
infect
se
clostridium
difficil
se
sepsi
se
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
attempt
shed
light
industrysponsor
vaccin
nonvaccin
drug
develop
program
classifi
diseas
biolog
famili
transmiss
type
classif
present
tabl
supplementari
materi
comput
po
use
classif
look
vaccin
po
transmiss
rout
see
figur
see
vaccin
diseas
transmit
anim
bite
highest
overal
po
se
wherea
vaccin
develop
diseas
transmit
contamin
food
water
find
compani
success
develop
nonvaccin
treatment
diseas
transmit
human
air
se
drug
develop
program
make
phase
regulatori
approv
see
figur
unfortun
base
four
drug
develop
program
may
indic
gener
trend
treatment
diseas
transmit
human
human
other
overal
po
se
approv
observ
diseas
transmit
anim
bite
contamin
food
water
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
classifi
vaccin
biolog
famili
infecti
agent
figur
see
reovirida
eg
rotaviru
rhabdovirida
eg
rabi
hepadnavirida
eg
hbv
three
biolog
famili
highest
overal
po
vaccin
se
se
se
respect
yet
see
vaccin
diseas
caus
agent
biolog
famili
retrovirida
eg
hiv
calicivirida
eg
noroviru
clostridiacea
eg
clostridium
difficil
coronavirida
eg
sar
mer
herpesvirida
eg
cmv
infect
togavirida
eg
chikungunya
consid
nonvaccin
po
biolog
famili
infecti
agent
see
figur
see
nonvaccin
therapi
poxvirida
eg
smallpox
herpesvirida
eg
cmv
infect
hepadnavirida
eg
hbv
highest
overal
po
se
se
se
respect
virus
reovirida
eg
rotaviru
coronavirida
eg
sar
mer
calicivirida
eg
noroviru
rhabdovirida
eg
rabi
togavirida
eg
chikungunya
famili
less
five
develop
program
approv
treatment
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
compani
produc
vaccin
therapeut
infecti
diseas
gradual
retreat
space
recent
year
number
compani
produc
vaccin
dwindl
past
decad
top
four
vaccin
compani
make
global
market
evalu
similarli
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
surpris
investor
unwil
invest
compani
produc
vaccin
treatment
infecti
diseas
given
econom
market
vu
et
al
gener
regard
lowmargin
product
low
growth
potenti
compar
treatment
therapeut
area
oncolog
cardiovascular
diseas
comparison
revlimid
blockbust
cancer
drug
multipl
myeloma
earn
billion
celgen
celgen
wherea
vaccin
antivir
portfolio
glaxosmithklin
top
vaccin
produc
sale
gener
billion
billion
revenu
respect
evalu
lack
invest
result
rel
low
number
develop
program
vaccin
treatment
infecti
diseas
industrysponsor
program
initi
past
two
decad
mere
industrysponsor
drug
develop
program
launch
period
studi
indic
technic
success
rate
unlik
barrier
invest
new
vaccin
treatment
infecti
diseas
unlik
cancer
drug
financi
risk
new
r
project
come
reduc
chanc
bring
drugind
pair
phase
market
overal
po
industrysponsor
vaccin
treatment
infecti
diseas
averag
therapeut
group
see
tabl
supplementari
materi
often
suggest
fundament
issu
behind
lack
invest
market
vaccin
treatment
infecti
diseas
simpli
lucr
enough
despit
expens
research
develop
need
largescal
product
weir
gruber
antiinfect
diseas
treatment
use
occasion
vaccin
compani
face
avalanch
liabil
lawsuit
hensley
wysocki
jr
furthermor
compani
merci
govern
price
decis
hu
remain
seen
nonindustrysponsor
research
allevi
issu
studi
show
se
se
nonindustrysponsor
vaccin
nonvaccin
infecti
diseas
develop
program
transit
phase
approv
respect
howev
may
result
select
bia
promis
vaccin
therapeut
initi
nonindustri
set
often
pursu
conjunct
industrysponsor
sponsor
wherea
commerci
less
promis
project
like
pursu
nonprofit
organ
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
world
today
never
greater
need
effect
vaccin
antiinfect
crisi
shown
infecti
diseas
still
potenti
caus
catastroph
larg
number
death
disrupt
daili
live
billion
hope
research
probabl
success
develop
infecti
diseas
therapeut
inform
stakehold
catalyz
innov
greater
invest
critic
underserv
field
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
apr
wong
siah
lo
page
right
reserv
reproduc
probabl
success
across
therapeut
group
attempt
find
correl
differ
number
industrysponsor
clinic
develop
program
initi
treatment
analog
number
vaccin
diff
defin
time
number
month
elaps
sinc
januari
test
five
regress
model
follow
specif
diff
constant
b
diff
constant
c
diff
constant
diff
constant
e
diff
g
time
g
local
linear
gaussian
kernel
model
perform
microsoft
excel
model
e
implement
use
statsmodel
packag
python
bandwidth
nonparametr
kernel
regress
select
use
leastsquar
crossvalid
method
result
regress
report
tabl
best
fit
model
model
e
indic
differ
number
nonvaccin
treatment
develop
program
initi
right
reserv
number
vaccin
program
initi
widen
januari
may
narrow
differ
number
initi
program
close
zero
decemb
possibl
due
withdraw
pharmaceut
compani
antibiot
busi
bankruptci
antibiot
compani
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
